NV-ENCONNEX
21.11.2019 17:02:07 CET | Business Wire | Press release
Enconnex announced today that it has acquired assets of Active Energy Solutions (AES), a division of Methode Electronics, Inc., solidifying the long-term relationship between the two firms. Under an exclusive distribution agreement with AES, Enconnex has been offering the AC6000 uninterruptible power supply (UPS) to its customers. Enconnex has established a new manufacturing facility in its Reno, Nev., headquarters and incorporated the product into its integrated data center solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191121005220/en/
“This acquisition is the logical extension of our strategic partnership with AES,” said Thane Moore, Director of Product Line Management, Enconnex. “The AC6000 is a robust yet eco-friendly UPS that offers the advanced features needed to support today’s IT and Data Center demands. We are also providing a firmware upgrade release to all existing customers of the AC6000 allowing them to benefit with the latest advancements.”
The AC6000 is the first line-interactive UPS that both protects IT equipment from power outages and supplements the electrical grid during periods of peak energy consumption with its peak shave technology. Its industrial-grade lithium-ion battery pack supplies up to 6kW of power for six full minutes — 330 percent longer than legacy lead-acid batteries. It offers fast recharge to 90 percent in less than one hour, and delivers up to seven years of maintenance-free battery life. It’s up to 75 percent lighter than UPSs that use lead-acid batteries, and has a compact design that takes up just 2U of rack space in the data center.
The patent-pending peak shave technology in the AC6000 uses advanced energy management techniques to transfer to battery power during peak loads, thus reducing overall energy costs. The AC6000 is designed to maintain battery cell power balance, and it provides integrated safety electronics and thermal management for individual cells. It features a multifunctional LCD panel that displays critical performance metrics and alerts, and it supports serial and SNMP communications for remote monitoring and management.
“With low total cost of ownership, substantial energy savings and pricing that’s competitive with lead-acid products, the AC6000 delivers ROI in as little as two years,” Moore said. “Its lithium-ion battery pack delivers greater energy efficiency and more than seven year battery life while taking up less space within the data center cabinet. We believe this is the ideal solution for both modern web-scale data centers and edge computing applications where space is at a premium.”
The AC6000 is CE and UL listed and is available for purchase across the globe. To learn more about the AC6000 and purchase today, visit Enconnex AC6000 UPS .
About Enconnex
Enconnex designs and manufactures high-quality, cost-efficient solutions for data center infrastructure, including racks, cabinets and accessories, and connectivity, power, cooling and containment products. Enconnex also integrates cutting-edge solutions from a short list of technology partners who are recognized as industry leaders. Headquartered in Reno, Nev., Enconnex has offices and distribution facilities strategically located worldwide to serve the needs of its global customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191121005220/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom